Moment Of Truth For Daiichi/AstraZeneca’s Enhertu In EU
Executive Summary
The EU marketing application for the HER2-targeted antibody drug conjugate has been fast-tracked and is now up for an opinion from the European Medicines Agency.
You may also be interested in...
Early EU Approval Wins In Line For Daiichi/AZ & Lilly
Advanced breast cancer treatment Enhertu and non-small cell lung cancer and thyroid cancer therapy Retsevmo are set to win conditional marketing authorizations in the EU shortly. The two drugs are among a number of new products that the European Medicines Agency has just recommended for approval.
Raft Of New Drugs To Learn EU Marketing Fate
ViiV Healthcare’s “last resort” HIV drug, fostemsavir, is one of 16 new medicines that are up for an opinion by the European Medicines Agency on whether they should be authorized for use across the EU.
Second Time Lucky For Dynavax’s Hep B Vaccine In EU?
The European Medicines Agency is set to decide whether Dynavax’s “fewer dose” Heplisav-B vaccine should be authorized for use across the EU – years after the company experienced a setback with its first attempt to get the vaccine approved.